HeartFlow today announced positive results from clinical studies evaluating its portfolio of coronary care technologies. Mountain View, California-based HeartFlow said the studies demonstrate the accuracy, utility and efficiency of its portfolio. The RevealPlaque, Decode and Smart-CT studies looked at the company’s coronary computed tomography angiography (CCTA)-based systems. HeartFlow presented results at the Society of Cardiovascular […]
HeartFlow
How did medtech SPAC mergers fare?
Over the past few years, special purpose acquisition corporations (SPACs) have found their way into the medtech space. These businesses — built to bring private companies public — raise initial public offerings (IPOs). They then go and acquire existing companies, taking them public in the process. The value of these mergers varies, but some in […]
HeartFlow closes $215M Series F funding round
HeartFlow announced today that it closed a $215 million Series F funding round led by Bain Capital Life Sciences. New investor Janus Henderson Investors also contributed to the round. Participating existing investors included Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management. J.P. Morgan acted as the sole placement […]
FDA clears HeartFlow’s AI-powered analysis tech
HeartFlow announced that the FDA granted 510(k) clearance to its AI-powered Plaque analysis and Roadmap Analysis products. Mountain View, California-based HeartFlow designed its technology around coronary computed tomography angiography (CCTA). It now offers non-invasive coronary artery anatomy, physiology and plaque information based on CCTA. The company said in a news release that it is the […]
The biggest medtech personnel moves so far in 2022
In the ever-changing world of medtech, those who are leading the companies are bound to move around a bit. At the end of last year, we compiled a list of medtech’s biggest personnel changes in 2021. So far in 2022, we’ve already seen a slew of major moves involving some of the space’s most powerful […]
HeartFlow announces new CEO
HeartFlow announced today that John Farquhar has been appointed as the company’s president and CEO, effective today. Farquhar, a former Medtronic executive, was appointed as COO of HeartFlow in August 2021 and has served as the company’s president and a member of the board since Jan. 1, 2022. According to a news release, co-founder and […]
HeartFlow SPAC deal is called off
HeartFlow and a special purpose acquisition company called Longview Acquisition Corp. have called off merger plans that would have taken the cardiac test company public. HeartFlow, in a news release out this evening, described the move as a mutual decision — a “result of current unfavorable market conditions.” Stock markets in the U.S. have been […]
HeartFlow appoints former Medtronic executive as COO
HeartFlow today announced that it has appointed John Farquhar as chief operating officer, effective immediately. Farquhar will be responsible for executing the strategic vision of the Redwood City, Calif.–based company — developer of the non-invasive HeartFlow FFRCT analysis. “We are thrilled to add an executive of John’s caliber and accomplishments to the HeartFlow leadership team,” […]
MedTech 100 roundup: Industry shatters all-time best with remarkable rise
The medtech industry’s steady growth provided optimism in recent weeks, but an unforeseen leap sees it hitting new heights now. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 16) at 145.88 points, a remarkable 27.1% rise week-over-week, registering by far the greatest increase the […]
HeartFlow to go public in $2.8B SPAC merger
HeartFlow today said that it will go public by merging with a SPAC called Longview Acquisition Corp. The merger is valued at $2.4 billion plus an estimated $400 million in cash after closing. The transaction is expected to deliver up to $599 million of gross proceeds to HeartFlow to accelerate the growth of its noninvasive, […]
FDA clears HeartFlow Planner
HeartFlow said yesterday that it won FDA clearance for its Planner tool for coronary artery disease intervention. The Redwood City, Calif.-based company developed FFRct, which works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing changes in flow across coronary lesions. The Planner virtual […]
